💊 Médicaments A-Z 🧬 Cibles 🛠 Outils 📚 Guides
Tous les médicaments Classes de médicaments Aires thérapeutiques Effets Indésirables
Guides Glossaire Chronologie
Comparaisons Parcours des médicaments Familles de médicaments
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Edoxaban

CHEMBL1269025 Phase 4 Approuvé Small molecule
Half-Life
10-14 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
548.1 g/mol
LogP
1.4
Phase
4

A direct oral anticoagulant that inhibits factor Xa, a key protein in the blood clotting cascade, used to prevent stroke in patients with atrial fibrillation and to treat blood clots in veins. It does not require routine blood monitoring unlike older blood thinners.

Masse moléculaire

548,0530 g/mol

LogP

1,40

TPSA

165,00 Ų

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Non-Small Cell Lung Cancer Chronic Kidney Disease Stroke Deep Vein Thrombosis / Pulmonary Embolism Type 2 Diabetes Hypertension Breast Cancer Heart Failure Atrial Fibrillation Prostate Cancer Colorectal Cancer

Classes de médicaments

B — B - Blood and Blood Forming Organs

Mécanisme d'action

Direct, selective inhibitor of Factor Xa preventing thrombin generation and clot formation.

Pharmacokinetics (PK)

Half-Life 10-14 hours

Pharmacodynamics (PD)

Mécanisme

Direct, selective inhibitor of Factor Xa preventing thrombin generation and clot formation.

Structure 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1

                

                

                
                

                    
InChI

                    
InChI=1S/C24H30ClN7O4S/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34)/t13-,15-,17+/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C24H30ClN7O4S

                    

                    
                    

                        
HBD / HBA

                        
3 / 8

                    

                    
                    

                        
Liaisons Rotatives

                        
5

                    

                    
                    
                    

                        
Atomes Lourds

                        
37

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Foire aux questions

                

                    
                    

                        
                        

                            
A direct oral anticoagulant that inhibits factor Xa, a key protein in the blood clotting cascade, used to prevent stroke in patients with atrial fibrillation and to treat blood clots in veins. It does not require routine blood monitoring unlike older blood thinners.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Direct, selective inhibitor of Factor Xa preventing thrombin generation and clot formation.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Edoxaban: Half-life: 10-14 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Edoxaban is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Warfarin
                            Small molecule
                        
                        
                        
                            Clopidogrel
                            Small molecule
                        
                        
                        
                            Apixaban
                            Small molecule
                        
                        
                        
                            Rivaroxaban
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1269025.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 10280735.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Avertissement médical

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.